Turning innovation spend into cash today and value tomorrow

In many growing businesses, the most valuable assets sit within development activity  software, platforms, data and proprietary processes. Without a disciplined approach to cost capitalisation, much of that spend is simply expensed. The result is often understated assets, suppressed EBITDA and a financial story that doesn’t fully reflect economic and financial reality.

It doesn’t have to be that way, however. “With the right policies, controls and governance, businesses can turn innovation spend into cash today and enterprise value tomorrow,” says Dominic Longley, S&W Head of Accounting Advisory.

R&D tax relief claims don’t fully address the challenge, because they are inherently retrospective. Claims are prepared after the spend has occurred and the accounting treatment is set, which makes it easy to view it as a standalone exercise.

A more strategic approach is to consider how well your accounts capture the value created through development.

Under IFRS, qualifying development costs must be capitalised. Under UK GAAP, there is a policy choice. Where businesses default to expensing, they risk understating both performance and asset value.

At the same time, changes in accounting policy can interact with R&D tax treatment, and misalignment between finance and tax increases the risk of challenge from auditors and HMRC.

Getting capitalisation right can materially impact reported results:

• Improved EBITDA as eligible costs move below the line
• A stronger balance sheet through recognition of development assets
• Better alignment between reported performance and long‑term investment

It also helps tell a clearer, more credible story to investors, lenders and acquirers, particularly in high‑growth, technology‑enabled businesses.

The central judgement is distinguishing between research (expensed), and development (capitalised once criteria are met).
In practice, this isn’t straightforward. Innovation is iterative, and there is rarely a clean transition point. Getting the judgement wrong can materially affect both earnings and asset values.

Equally important is discipline around exclusions. Marketing, training, business development and most overheads typically fall outside scope and must be consistently identified.

Applying the standards requires consistent, evidence‑based judgement, including:

• When future economic benefits are probable
• Whether costs are directly attributable
• Whether expenditure can be measured reliably

These judgements evolve as projects progress and a business grows, making documentation critical. This is also where accounting and R&D tax begin to overlap. While capitalised costs may still qualify as revenue for tax, alignment of data, systems and project understanding is essential to avoid friction.

Audit scrutiny in this area is high, given the level of judgement and increasing asset values. Clear documentation reduces the risk of late adjustments and supports a smoother audit.

In practice, that means:

Clearly defined and documented accounting policies

Robust criteria for distinguishing research and development

Structured project tracking and approvals

Reliable time recording

Contemporaneous evidence supporting key decisions

This same discipline is critical in a transaction context. Buyers will closely examine capitalised development costs, and weak or inconsistent policies can lead to challenges, EBITDA adjustments or asset write‑downs during due diligence.

By contrast, however, a well‑documented and consistently applied framework builds confidence in the sustainability of earnings and the integrity of the balance sheet. It reduces deal friction, supports the valuation and helps protect against price chips.

In short, strong capitalisation policies don’t just support compliance; they help preserve enterprise value.

R&D tax relief and cost capitalisation serve different but complementary purposes. R&D tax relief delivers cash, while cost capitalisation makes long‑term value visible.

When aligned, they drive stronger reporting, better governance and a financial narrative that stands up to audit and transaction scrutiny. For innovative businesses it should be a key part of exit planning, according to Jack Dessay, Head of Technology for M&A Advisory at S&W.

“Reviewing and putting in place appropriate policies, robust controls and strong governance is an important aspect of exit readiness and can have a significant positive impact on valuation and the outcome of a transaction,” he says.

But it is also simply an exit issue. A robust approach to cost capitalisation, underpinned by clear policies, strong controls and good documentation, ensures financial statements reflect the reality of the business and that performance is credible.

It turns innovation spend into visible enterprise value, supporting both today’s cash flow and tomorrow’s deal outcome.